{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:28:23Z","timestamp":1789597703621,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40273-021-01098-3","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T08:14:50Z","timestamp":1634631290000},"page":"509-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mogamulizumab for Previously Treated Mycosis Fungoides and S\u00e9zary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2175-7999","authenticated-orcid":false,"given":"Sabine E.","family":"Grimm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Witlox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Chalker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Hiligsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Wijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Ahmadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Syndikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Kleijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela A.","family":"Joore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"1098_CR1","unstructured":"National Institute for Health and Care Excellence. Mogamulizumab for previously treated mycosis fungoides and S\u00e9zary syndrome [ID1405]. London: National Institute for Health and Care Excellence. 2021. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10305\/documents. Accessed 7 Jun 2021."},{"issue":"9","key":"1098_CR2","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","volume":"19","author":"YH Kim","year":"2018","unstructured":"Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192\u2013204.","journal-title":"Lancet Oncol"},{"issue":"10094","key":"1098_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555\u201366.","journal-title":"Lancet"},{"key":"1098_CR4","unstructured":"US Food and Drug Administration. Poteligeo (mogamulizumab-kpkc). Labeling [Internet]: US Food and Drug Administration, 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761051Orig1s000Lbl_.pdf. Accessed 30 Jan 2020"},{"issue":"28","key":"1098_CR5","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","volume":"34","author":"S Fuji","year":"2016","unstructured":"Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426\u201333.","journal-title":"J Clin Oncol"},{"key":"1098_CR6","unstructured":"Phillipo D, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE [Internet]. Sheffield: Decision Support Unit, School of Health and Related Research, University of Sheffield (ScHARR), 2016. Accessed 21 Jan 2020."},{"key":"1098_CR7","unstructured":"National Institute for Health and Care Excellence. Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma. NICE technology appraisal guidance 577. Final appraisal document. London: National Institute for Health and Care Excellence. 2019. https:\/\/www.nice.org.uk\/guidance\/ta577\/documents\/final-appraisal-determination-document. Accessed 21 Jan 2020."},{"key":"1098_CR8","unstructured":"European Medicines Agency. Poteligeo 4 mg\/mL concentrate for solution for infusion: EPAR - Product Information. Annex I. Summary of product characteristics. Amsterdam: European Medicines Agency.s 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/poteligeo-epar-product-information_en.pdf. Accessed 21 Jan 2020."},{"key":"1098_CR9","unstructured":"National Institute for Health and Care Excellence. Mogamulizumab for treated mycosis fungoides or S\u00e9zary syndrome cutaneousT-cell lymphoma. Final scope. London: National Institute for Health and Care Excellence. 2019. https:\/\/www.nice.org.uk\/guidance\/gid-ta10305\/documents\/final-scope. Accessed 21 Jan 2020"},{"key":"1098_CR10","unstructured":"NHS Digital. Hospital Episode Statistics (HES). NHS Digital. 2019. https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics. Accessed 21 Jan 2020."},{"key":"1098_CR11","doi-asserted-by":"crossref","unstructured":"Latimer N, Abrams K. NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching. Sheffield: NICE Decision Support Unit. 2014. http:\/\/www.nicedsu.org.uk. Accessed 21 Jan 2020.","DOI":"10.1016\/j.jval.2013.08.013"},{"key":"1098_CR12","unstructured":"National Institute for Health and Care Excellence. Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma. NICE technology appraisal guidance 577. London: National Institute for Health and Care Excellence. 2019. https:\/\/www.nice.org.uk\/guidance\/TA577. Accessed 7 Jun 2021."},{"issue":"5","key":"1098_CR13","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health"},{"key":"1098_CR14","unstructured":"NHS Improvement. Reference costs 2017\/18. London: NHS Improvement. 2018. https:\/\/improvement.nhs.uk\/resources\/reference-costs\/. Accessed 21 Jan 2020."},{"key":"1098_CR15","unstructured":"Personal Social Services Research Unit. Unit costs of health and social care 2018. Canterbury: University of Kent, 2018. https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2018\/. Accessed 21 Jan 2020."},{"key":"1098_CR16","unstructured":"Joint Formulary Committee. British National Formulary. London: BMJ Group and Pharmaceutical Press. 2019. https:\/\/bnf.nice.org.uk\/. Accessed 21 Jan 2020."},{"key":"1098_CR17","unstructured":"Department of Health and Social Care. Drugs and pharmaceutical electronic market information tool (eMIT). London: Department of Health and Social Care. 2019. https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit. Accessed 21 Jan 2020."},{"issue":"2","key":"1098_CR18","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1177\/0962280214557578","volume":"26","author":"NR Latimer","year":"2017","unstructured":"Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, et al. Adjusting for treatment switching in randomised controlled trials - a simulation study and a simplified two-stage method. Stat Methods Med Res. 2017;26(2):724\u201351.","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"1098_CR19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jval.2019.10.015","volume":"23","author":"TR Sullivan","year":"2020","unstructured":"Sullivan TR, Latimer NR, Gray J, Sorich MJ, Salter AB, Karnon J. Adjusting for treatment switching in oncology trials: a systematic review and recommendations for reporting. Value Health. 2020;23(3):388\u201396.","journal-title":"Value Health"},{"key":"1098_CR20","unstructured":"Pennington B, Wong R. Modelling carer health-related quality of life in NICE Technology Appraisals and Highly Specialised Technologies. Sheffield: Decision Support Unit, School of Health and Related Research, University of Sheffield (ScHARR). 2019. http:\/\/nicedsu.org.uk\/modelling-carer-health-related-quality-of-life\/. Accessed 7 Jun 2021."},{"key":"1098_CR21","unstructured":"National Institute for Health and Care Excellence. Mogamulizumab for previously treated mycosis fungoides and S\u00e9zary syndrome. Final appraisal document. London: National Institute for Health and Care Excellence. 2021. https:\/\/www.nice.org.uk\/guidance\/gid-ta10305\/documents\/final-appraisal-determination-document. Accessed 28 Jun 2021."}],"updated-by":[{"DOI":"10.1007\/s40273-022-01144-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000}}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01098-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01098-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01098-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T18:31:09Z","timestamp":1652293869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01098-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1098"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01098-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40273-022-01144-8","asserted-by":"object"}]},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"26 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40273-022-01144-8","URL":"https:\/\/doi.org\/10.1007\/s40273-022-01144-8","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme. Please visit the HTA programme website for further project information ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SG, WW, RW, AC, MH, BW, CA, SR, NA, SD, IS, JK, and MJ have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analysed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}